15 September 2021 | News
Expects 5 per cent additional growth in revenue
Image credit: shutterstock
Mumbai headquartered ENTOD Pharmaceuticals has launched their super-speciality ophthalmic surgical division, 'HyTek' which caters to hi-tech solutions for ophthalmic surgical needs.
ENTOD's HyTek division will especially focus on the products which are required during ophthalmic surgical procedures like cataracts, refractive surgeries etc.
"The launch of the new division is expected to contribute an additional 5% growth in revenue initially and we’re expecting more with expansion,” said Executive Director of ENTOD Pharmaceuticals, Nikkhil K. Masurkar.
The HyTek division has been launched in Mumbai and subsequent extension plans are in progress for other metro and sub-metro cities. Through products manufactured at their state-of-the-art WHO GMP and US FDA approved manufacturing plants, ENTOD aims to provide innovative ophthalmic medicines in countries where there is an acute shortage of such formulations.
Masurkar further said, "ENTOD is a speciality pharmaceutical company however, our main focus has always been ophthalmology. We have huge expectations with the launch of this new division. It will allow us to strengthen ENTOD's collaboration with the large ophthalmic medical fraternity of India and around the world."